A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds

Bioanalysis

Volumn 4, Issue 14, 2012, Pages 1747-1761

  Grubb, Mary F ^a   Humphreys, William G ^a   Josephs, Jonathan L ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; MIRTAZAPINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL SUSPENSION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LIVER CLEARANCE; LIVER MICROSOME; METABOLITE; MICHAELIS CONSTANT; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; AUTOMATION; BIOTRANSFORMATION; BUSPIRONE; CHEMISTRY TECHNIQUES, ANALYTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; MIANSERIN; MICROSOMES, LIVER; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; VERAPAMIL;

EID: 84865020268     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.134     Document Type: Article

References (35)

1. Bajrami B, Zhou L, Schenkman JB, Rusling JF. Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format. Anal. Chem. 8, 9921-9929 (2009
2. Plumb RS, Mather J, Little D et al. A novel LC-MS approach for the detection of metabolites in DMPK studies. Bioanalysis 2, 1767-1778 (2010
3. Tiller PR, Romanyshyn LA. Liquid chromatography-tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process. Rapid Commun. Mass Spectrom. 16, 1225-1231 (2002
4. Trunzer M, Faller B, Zimmerlin A. Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J. Med. Chem. 52, 329-335 (2009
5. Bateman KP, Kellmann M, Muenster H, Papp R, Taylor L. Quantitative-qualitative data acquisition using a bench top orbitrap mass spectrometer. J. Am. Soc. Mass Spectrom. 20, 1441-1450 (2009
6. Zhu M, Zhang H, Humphreys WG. Drug metabolite profiling and identification by high-resolution mass spectrometry. J. Biol. Chem. 286, 25419-25425 (2011
7. Sanders M, Shipkova PA, Zhang H, Warrack BM. Utility of the hybrid LTQ-FTMS for drug metabolism applications. Curr. Drug Metab. 7, 547-555 (2006
8. Obach RS, Baxter JG, Liston TE et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283, 46-58 (1997
9. Tang K, Page JS, Smith RD. Charge competition and the linear dynamic range of detection in electrospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 15, 1416-1423 (2004
10. Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J. Pharmacol. Exp. Ther. 303, 1130-1137 (2002
11. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Human Psychopharmacol. 10, S83-S96 (1995
12. Delbressine LPC, Moonen MEG, Kaspersen FM et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Invest. 15, 45-55 (1998
13. Giorgi M, Yun H. Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: A pilot study. Veterinary J. 192(2), 239-241 (2011
14. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan and verapamil. Clin. Pharmacol. Ther. 66, 40-50 (1999
15. Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+)-verapamil after intravenous administration. Br. J. Clin. Pharmacol. 17, 453-458 (1984
16. Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, McLean AJ. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug Metab. Dispos. 18, 1093-1100 (1991
17. Bai S, Lankford SM, Johnson LM. Pharmacokinetics of the enantiomers of verapamil in the dog. Chirality 5, 436-442 (1993
18. Ling S, Jamali F. Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: An alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab. Dispos. 33, 579-586 (2005
19. Bhatti MM, Foster RT. Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. Biopharmaceutics Drug Dispos. 18, 387-396 (1997
20. Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33, 1304-1311 (2005
21. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994
22. Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab. Dispos. 17, 634-640 (1989
23. Zhu M, Zhao W, Jimenez H et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos. 33, 500-507 (2005
24. Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260, 1052-1057 (1992
25. Hu Q, Noll RJ, Li H, Makarov A, Hardman M, Cooks RG. The orbitrap: A new mass spectrometer. J. Mass Spectrom. 40, 430-443 (2005
26. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceut. Res. 10, 1093-1095 (1993
27. Mayol RF, Adamson DS, Gammans RE, LaBudde JA. Pharmacokinetics and disposition of 14C-buspirone HCl after intravenous and oral dosing in man. Clin. Pharmacol. Ther. 35, 210 (1985
28. Jajoo HK, Blair IA, Klunk LJ, Mayol RF. In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 20, 779-786 (2005
29. Kerns EH, Rourick RA, Volk KJ, Lee MS. Buspirone metabolite structure profile using a standard liquid chromatographic-mass spectrometric protocol. J. Chromatogr. Biomed. Appl. 698, 133-145 (1997
30. Goldthwaite CA, Hsieh F-Y, Womble SW, et al. Liquid chromatography- chemical reaction interface mass spectrometry as an alternative to radioisotopes for quantitative drug metabolism studies. Anal. Chem. 68, 2996-3001 (1996
31. Dahl M-L, Voortman G, Alm C et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin. Drug Invest. 13, 37-46 (1997
32. Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6 and 3A4. Drug Metab. Dispos. 28, 1168-1175 (2000
33. Sandker GW, Vos RME, Delbressine LPC, Slooff MJH, Meijer DFK, Groothius GMM. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: Analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica 24, 143-155 (1994
34. McIlhenny HM. Metabolism of [14C] verapamil. J. Med. Chem. 14, 1178-1184 (1971
35. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ. The metabolism of DL-[14C]verapamil in man. Drug Metab. Dispos. 7, 145-148 (1979